Drug or treatment

Deucravacitinib clinical trials

• 13Clinical trials
• 28Countries

Newest trials

All recruiting trials (13)

• Deucravacitinib for scarring hair loss (frontal fibrosing and central centrifugal alopecia)

  This trial will test whether taking deucravacitinib once daily for 48 weeks helps adults with frontal fibrosing alopecia or central centrifugal cicatricial alopecia.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07508488

• Deucravacitinib added to current PsA treatment for difficult-to-control disease

  This study tests whether adding deucravacitinib to a patient’s existing Psoriatic Arthritis treatment can improve symptoms and quality of life for adults with hard-to-control disease.

  Recruiting Phase 4 University of Texas Southwestern Medical Center · Dallas, Texas · NCT07280702

• Long-term safety of deucravacitinib versus ustekinumab for plaque psoriasis (PRAGMATYK)

  This study will test whether deucravacitinib or ustekinumab has better long-term safety for adults with moderate-to-severe plaque psoriasis who have cardiovascular risk factors.

  Recruiting at 323 sites Phase 3 Bristol-Myers Squibb · Birmingham, Alabama and 410 other locations · NCT07116967

• Deucravacitinib safety during pregnancy.

  This project will see if taking deucravacitinib during pregnancy affects pregnancy and baby outcomes for people with psoriasis.

  Recruiting Bristol-Myers Squibb · La Jolla, California · NCT07017699

• Deucravacitinib for teens with moderate to severe plaque psoriasis

  This trial will test whether deucravacitinib helps teens with moderate to severe plaque psoriasis while tracking safety and drug levels.

  Recruiting at 89 sites Phase 3 Bristol-Myers Squibb · Birmingham, Alabama and 132 other locations · NCT06979453

• Continued deucravacitinib treatment for people with systemic or cutaneous lupus who completed earlier trials

  This open-label extension lets people with systemic lupus or discoid/subacute cutaneous lupus who finished specific earlier trials continue taking deucravacitinib to see if ongoing treatment remains safe and tolerable.

  Recruiting at 2 sites Phase 4 Bristol-Myers Squibb · Farmington, Connecticut and 3 other locations · NCT06875960

• Evaluating Deucravacitinib for Juvenile Psoriatic Arthritis in Children

  This study is testing if a new medication called Deucravacitinib can help children with juvenile psoriatic arthritis who haven't had success with other treatments.

  Recruiting at 29 sites Phase 3 Bristol-Myers Squibb · Lancaster, California and 47 other locations · NCT06869551

• Evaluating the effectiveness of deucravacitinib for plaque psoriasis in adults in France

  This study is testing how well deucravacitinib works for adults with moderate-to-severe plaque psoriasis in real life.

  Recruiting at 39 sites Bristol-Myers Squibb · Amiens and 47 other locations · NCT06701513

• Comparing the effectiveness of deucravacitinib and apremilast for plaque psoriasis in adults in Japan

  This study is testing whether a new medication called deucravacitinib works better than apremilast for adults with plaque psoriasis in Japan.

  Recruiting at 2 sites Bristol-Myers Squibb · Minato-ku, Tokyo and 1 other locations · NCT06382987

• Evaluating the safety and effectiveness of Sotyktu for plaque psoriasis in Korea

  This study is testing if a new medication called Sotyktu is safe and effective for adults in Korea with moderate-to-severe plaque psoriasis who need treatment.

  Recruiting Bristol-Myers Squibb · Seoul and 1 other locations · NCT06258668

• Treatment of psoriasis with deucravacitinib

  This study is testing how well a new medication called deucravacitinib can change immune cell behavior in people with moderate to severe psoriasis.

  Recruiting Phase 4 University of California, San Francisco · San Francisco, California · NCT05858645

• Comparing the effectiveness of two medications for plaque psoriasis

  This study is testing whether deucravacitinib or apremilast works better for adults with plaque psoriasis who are starting treatment.

  Recruiting Bristol-Myers Squibb · Waltham, Massachusetts · NCT05744466

• Evaluating Deucravacitinib for Pediatric Plaque Psoriasis

  This study is testing a new medication called Deucravacitinib to see if it helps children and teens with moderate to severe plaque psoriasis feel better and is safe for them to use.

  Recruiting at 45 sites Phase 3 Bristol-Myers Squibb · Ciudad Autonoma de Buenos Aires, Buenos Aires and 64 other locations · NCT04772079

Quick answers

How many clinical trials of Deucravacitinib are recruiting right now?

13, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 28 countries. The most sites are in United States (9 trials), Brazil (4 trials), Germany (4 trials), Romania (4 trials), Spain (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 4, Phase 4: 3, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →